Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Board

Company Overview

Team

Values

Clinical Advisers

Corporate Directory

Corporate Governance

About Us

Presentations

In the News

Video Updates

Communication

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Clinical Trial

Home

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

Amplia CEO & MD, Dr Chris Burns, visited the Calvary Mater Hospital in Newcastle last week, where patient enrolment is now open as part of the Phase 2a portion of Amplia’s ACCENT clinical trial of narmafotinib in pancreatic cancer patients.

Thank you to journalist @Risa Utama of @NBN News for making the time to visit the hospital to learn more about the ACCENT trial, and how Amplia is working towards improving treatment outcomes for pancreatic cancer patients, like Lorraine Gibbs.

Lorraine was so generous with her time and is a tireless advocate for clinical research that can assist people facing a pancreatic cancer diagnosis.

NBN News Interview